drugset / Trial / NCT06939829

A Multicenter Clinical Study on the Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections

NCT06939829

Phase 4 Not yet recruiting 1200 enrolled Southeast University, China
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to determine whether continuous infusion of ceftazidime-avibactam (CAZ-AVI) could improve clinical outcomes in critically ill patients compared with intermittent infusion.

Timeline

Start
2025-05-01
Primary completion
2027-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ceftazidime-avibactam Other / unclassified 2.5 g

Indications

No indication recorded.